 Home > Biochemical Engineering > Polypeptide > JNJ-2113 is the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, blocking IL-23 signaling

JNJ-2113 is the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, blocking IL-23 signaling

Name: JNJ-2113 is the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, blocking IL-23 signaling
Brand: focuses
SKU: pr2508291448
Price: 1 USD
Availability: InStock

2 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2763602-16-8

Grade:

Pharmaceutical Grade

Content:

99%

Port:

ningbo

Brand:

focuses

Packaging:

as requires

Price valid (until):

2025-09-29

Contact Supplier

 Chat Now

Fujian Genohope Biotech Ltd.

Company Type:

Manufactory

Location:

China

Payment Terms:

TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

Average Lead Time:

2 days

Qualification:

Main Products:

Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

 Visit Store

Product Details
Seller Information
Inquiry History

Description
Product Detail

Chinese Name: JNJ-77242113/JNJ-2113/PN-235
English Name: Icotrokinra
‌Amino Acid Sequence: Ac-Pen-Asn-Thr-Trp(7-Me)-Lys(Ac)-Pen-Phe(4-amino ethoxy)-2Nal-ThpGly-Glu-Asn-3Pal-Sar-NH2 (Pen1&Pen6 bridge)
CAS number: 2763602-16-8
Manufacturing Process: chemical synthesis
Mechanism of Action: By achieving highly selective blockade of IL-23R with high binding affinity (KD=7.1 pM), it inhibits the inflammatory signaling pathway
Indication：Psoriasis
Preparation：JNJ-77242113-AAC Tablet‌
Originator Drug Development Status: Phase III Clinical Trials

Our Factory

Fujian Genohope Biotech Ltd was established in 2019, It was co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation. The company is located in the national "Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone" in Putian City, Fujian Province. The company has 260 employees, and in 2023, the company was selected as a Specialized in special innovative enterprises in Fujian Province.

The company focuses on High potency polypeptide API/solution, and sells polypeptide API/solution and preparation production services to the global market. The company covers a total area of 55 mu, with a total construction area of about 70,000 square meters, and has built about 800 square meters of R & D center, 1,000 square meters of quality control center and 3,300 square meters of GMP production workshop. At present, 13 production lines have been built, including 7 production lines for the preparation of recombinant peptide API and fully synthetic peptide API and 6 lines for injections. In addition, the company also has a large anti-tumor injection workshop, a small multi-purpose injection workshop, a large multi-purpose injection workshop. The construction and operation management of the production line meet the regulatory requirements of the global drug market and meet the double registration and declaration of China and the United States. Also can meet the customer registration and sales at home and abroad.

Product superiority：

At present, the company's main products are Semaglutide, Tirzepatide, Retatrutide, cosmetic medicine microspheres, collagen. In particular, the company has the advantage of mature 2 processes preparation of Semaglutide API, Semaglutide API registered in the US FDA (DMF No. : 040957),Tirzepatide API registered in the US FDA (DMF No. : 040503),

Semaglutide API has the following three characteristics: low price, high quality, and large production capacity (tonnage). Tirzepatide API is well received favourable reviews in the pharmaceutical industry of polypeptide .

Our Certificate

FAQ

Q: What does semaglutide do to your body?

A: Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy.

Q: What is the dark side of semaglutide?

A: Pancreatitis (swelling of the pancreas) may occur while you are using this medicine. Check with your doctor right away if you have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.

Q: Who cannot take semaglutide?

A: Thyroid cancer or if someone in your family had thyroid cancer. An unusual or allergic reaction to semaglutide, other medications, foods, dyes, or preservatives. Pregnant or trying to get pregnant. Breast-feeding.

Q: Why do I feel so bad on semaglutide?

A: However, semaglutide also affects the gastrointestinal tract by increasing the amount of glucagon. This has two effects on the digestive tract. First, it slows down the movement of food through your gut, which can lead to nausea, vomiting, and diarrhea.

Q: Can semaglutide be harmful?

A: Nausea, vomiting, and diarrhea are the most common semaglutide side effects. But they usually subside after a few weeks of using the medication. Although rare, serious side effects are possible. Some may require immediate medical attention, such as pancreatitis and allergic reactions.

Q: Can semaglutide damage your pancreas?

A: Does Semaglutide Damage Your Pancreas? Semaglutide has been associated with pancreatitis, which is an inflammation of the pancreas. While pancreatitis can cause damage to the pancreas, the occurrence of this side effect due to semaglutide is considered uncommon.

Q: Can I lose 50 lbs on semaglutide?

A: According to clinical trials, people on a weekly semaglutide dosage can expect to lose an average of 5–10% of their body weight. Patients who were overweight lost 5.9% of their body weight after three months of weekly semaglutide injections. The average weight loss was 10.9% after 6 months of weekly injections.

Q: Is metformin as good as semaglutide?

A: Between these two medications, semaglutide produces more significant weight loss than metformin, but metformin tends to be a more affordable option. But patients can also opt to combine these drugs to maximize their effects with a proper treatment plan.
Research & Reference Note

JNJ-2113 is the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, blocking IL-23 signaling is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sources

PubChem

ClinicalTrials.gov

FDA Drugs@FDA

NIH
Disclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
Basic Info

Product Name:
New peptide drugs CAS 2763602-16-8, Ac-Pen-Asn-Thr-Trp(7-Me)-Lys(Ac)-Pen-Tyr(4-EtNH2)-2-Nal-ThpGly-Glu-Asn-3-Pal-Sar-NH2Bu)-AEEA-AEEA]-OH

CAS No.:
2763602-16-8

Categories:
Polypeptide
Seller Information

Business Type:
Manufactory

Main Products:
Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

Location:
NO.288,Renyang, Binglun Village, Hushi Town, Xiuyu DistrictPutian City, Fujian Province 351146, China (CHN)

Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
2 days

Total Annual Revenue:
$25 million-$50 million

Total Employees:
201-300

Year of Establishment:
2019

Company Certificates
- DMF ACKNOWLEDGEMENT
- Notice of GMP Compliance Inspection
Company Profile

Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province.

The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.

In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.

Inquiry History

2 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	IL-23 inhibitor peptide	100 PCS	Apr 16, 2026
India	Icotrokinra	1 KG	Jul 3, 2026

Post an enquiry for this product

More Choices

Product Name	Grade / Content	Supplier Name	Details
Icotrokinra	Pharmaceutical Grade/99.9	Echemi Pharmaceutical	Inquiry
Wholesale High Quality IL-23 Receptor Antagonist Powder CAS 2763602-16-8	Pharmaceutical Grade/99	NATURE INDUSTRIAL LIMITED	Inquiry
Jinlan 98+ EP/BP/USP Icotrokinra (JNJ2113)	medical grade/98	Hangzhou JINLAN Pharm-Drugs Technology Co., Ltd	Inquiry

Hot Searches: methyl chloride; sds for styrene; buy sodium nitrite; buy turinabol; dishwashing dispersants; acetic acid bulk; glp-1 retatrutide where to buy; specialty chemical products; ethylene vinyl acetate price; ethyl acetate cost; na 931 peptide for sale; gallium iii fluoride

JNJ-2113 is the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, blocking IL-23 signaling

Product Details

Seller Information

Inquiry History

Our Factory

Our Certificate

More Choices

More from this Seller